Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

By J. Wilding, R. Batterham, M. Davies, L. Gaal, K. Kandler, Katerina Konakli, I. Lingvay, B. McGowan, T. Kalayci Oral, J. Rosenstock and 4 more. Diabetes, obesity and metabolism, 2022

843 citations recorded by the source corpus.

To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/affabf9a514a6d5a047b73f03a1755c01264d89b